Synthesis and Application of Novel Arginine Vasopressin Receptor 1A (AVPR1A) Antagonists
1Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Road, Atlanta, Georgia 30322, United States.
Abstract:
Arginine Vasopressin Receptor 1A (AVPR1A) is a member of G-protein-coupled receptors (GPCRs) that binds arginine vasopressin (AVP) and is primarily related to cardiovascular function, glycogenolysis, and social behaviors. This patent describes the synthesis of a series of AVPR1A antagonists and their applications in related disease treatment.
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Vasodilators
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Antihypertensive Drugs: Direct Renin Inhibitors


